Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a nasal swab stop a superbug? new trial aims to find out

NCT ID NCT06282510

Disease control Sponsor: Mary K Hayden Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a 5-day course of a nasal antiseptic (povidone iodine) can reduce or eliminate Candida auris, a drug-resistant fungus, from the nose of colonized patients. Researchers will enroll 120 adults with a history of C. auris colonization or infection. The goal is to see if this simple treatment can lower the amount of fungus on the body and potentially reduce spread.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
povidone iodine (10%) nasal antiseptic
What this could lead to
If successful, this could provide a simple way to reduce Candida auris on the body, potentially lowering infection risk in healthcare settings.
What could go wrong
This is a small, early-phase trial focused on colonization, not infection. The antiseptic may not eliminate the fungus from all body sites, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * History of C. auris colonization or infection * Patient in a participating facility Exclusion Criteria: * History of severe allergy to iodine-based products, defined as anaphylaxis or rash * Currently breastfeeding or pregnant * Non-English language speaking

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Candida auris infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Asymptomatic Infections Candida auris infection candidiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Candida auris infection Colonization, asymptomatic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • RML Specialty Hospital

    RECRUITING

    Chicago, Illinois, 60624, United States

  • RML Specialty Hospital

    RECRUITING

    Hinsdale, Illinois, 60521, United States

  • Rush University Medical Center

    RECRUITING

    Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.